Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

Cancer Immunology, Immunotherapy

Volumn 54, Issue 3, 2005, Pages 254-264

  Ramanathan, Ramesh K ^a   Lee, Kenneth M ^b   McKolanis, John ^c   Hitbold, Elizabeth ^c   Schraut, Wolfgang ^b   Moser, Arthur J ^b   Warnick, Elizabeth ^a   Whiteside, Theresa ^a   Osborne, Jennifer ^a   Kim, Hyoung ^a   Day, Roger ^d   Troetschel, Monica ^a   Finn, Olivera J ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Biostatistics Facility   (United States)

Author keywords

Clinical trial; Immune response; Pancreatic cancer; Peptide vaccine

Indexed keywords

ADJUVANT; CD8 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MUCIN 1; PEPTIDE; SB AS2; VACCINE;

ANTIBODY SPECIFICITY; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ERYTHEMA; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SURVIVAL RATE; T LYMPHOCYTE; VACCINATION;

AGED; CA-15-3 ANTIGEN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HEPATITIS B; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE SYSTEM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY; LIPID A; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDES; RADIOTHERAPY, ADJUVANT; SAPONINS; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 19944433959     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0581-1     Document Type: Conference Paper

References (22)

1. Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 86:7159-7163
2. Barratt-Boyes SM, Vlad A, Finn OJ (1999) Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin Cancer Res 5:1918-1924
3. Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, Ballou WR, Holland CA, Kester KE, Voss G, Momin P, Greenwood BM, McAdam KP, Cohen J (1999) A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS, S/SBAS2 in semi-immune adults in The Gambia. Am J Trop Med Hyg 61:865-878
4. Edwards D, Berry JJ (1987) The efficiency of simulation-based multiple comparisons. Biometrics 43:913-928
5. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61-89
6. Gendler SJ (2001) MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6:339-353
7. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT (1996) A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298-304
8. Hiltbold EM, Ciborowski P, Finn OJ (1998) Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res 58:5066-5070
9. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ (2000) The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 165:3730-3741
10. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'Reilly S, Abrams RA, Pardoll DM, Cameron JL, Yeo CJ (2001) Novel allogeneic granulocyte- macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19:145-156
11. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics. CA Cancer J Clin 52:23-47
12. Johnson C (1997) Prognosis in pancreatic cancer. Lancet 349:1027-1028
13. Kalser MH, Ellenberg SS (1985) Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903
14. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776-782
15. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ (1994) Humoral immunity against a tandem repeat eitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856-2860
16. Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J (1999) Potent induction of focused Th1-type cellular and humoral immune responses by RTS, S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180:1656-1664
17. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. European Study Group for Pancreatic Cancer. Lancet 358:1576-1585
18. Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61:4756-4760
19. Schmielau J, Nalesnik MA, Finn OJ (2001) Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 7:933s-939s
20. Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA (2001) Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 19:1848-1854
21. Soares MM, Mehta V, Finn OJ (2001) Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166:6555-6563
22. Taylor-Papadimitriou J, Finn OJ (1997) Biology, biochemistry and immunology of carcinoma-associated mucins. Immunol Today 18:105-107